NERLYNX: The Power to Prevent Recurrence*
NERLYNX is an oral, extended adjuvant therapy, meaning it is designed to be taken after your adjuvant Herceptin® treatment (following surgery). With NERLYNX, you can help further reduce the risk that your breast cancer will return.
What is NERLYNX?
NERLYNX is a small-molecule, targeted therapy that enters and works inside the cell to permanently stop HER2 protein signals.†
People with HER2+ breast cancer have a gene that causes their cells to make too much HER2 protein:
- HER2 is a protein that signals cells to grow and divide
- When a gene mutation causes too much HER2 protein, cells grow more aggressively than normal
By blocking HER2 protein signals with NERLYNX, breast cancer cells don't grow and divide as rapidly.
NERLYNX was shown in preclinical trials to possibly cross the blood-brain barrier and enter the brain. Up to 50% of women with HER2+ breast cancer will eventually have a recurrence in the brain.
Download a NERLYNX brochure
Your resource to help you get started on treatment.
The Benefits of NERLYNX
NERLYNX was studied in a clinical trial of 2,840 women who had early-stage HER2+ breast cancer and had undergone treatment with trastuzumab. The phase 3 trial examined the safety and effectiveness of NERLYNX by comparing women who took NERLYNX with women who were given a placebo (which did not contain the medicine in NERLYNX). Participants were selected to receive NERLYNX randomly and were not told whether they were receiving the medicine or a placebo.
In the clinical trial, NERLYNX reduced the risk of cancer returning by 34% at 2 years for all women studied with HER2+ breast cancer.‡
The clinical trial also looked at a subset of women with HER2+ breast cancer who were also hormone receptor positive (HR+) and found there was a 42% reduction in the risk of recurrence at 5 years.‡,§
By committing to NERLYNX, you can be confident in knowing you are doing everything you can to lower your risk of your cancer coming back.
*Recurrence is defined as the cancer coming back or resulting in death.
†NERLYNX targets HER2+ cancer cells, but may also affect healthy cells.
‡These are relative benefits. In absolute numbers, 94.2% of all people studied who were HER2+ and took NERLYNX had no return of cancer after 2 years, compared to the 91.9% of people on a placebo who had no return of cancer. After 5 years, 90.8% of all people studied who were HER2+ and HR+ and took NERLYNX had no return of cancer, compared to the 85.7% of people on a placebo who had no return of cancer.
§5-year data are based on an exploratory analysis of people who were HR+ and had completed a trastuzumab-based treatment 1 year or less prior to treatment with NERLYNX. Of this HER2+, HR+ population, 95% were also on endocrine therapy.
Mentor Program
If you are considering or have started treatment, and have questions about what to expect, speak with a mentor.
Connect now
Stay Connected
Sign up to learn about support offerings and get updates specific to your HER2+ breast cancer.
Sign up now
